Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455299 | 0.84 | GABRP (0.42) | SMN1; SMN2GABRPGABRDTNKSPARP1 | |
| SCHEMBL21296037 | 0.84 | NOTUM (0.40) | CYP3A4TP53CYP1B1HPGDSMN1; SMN2 | |
| SCHEMBL21295803 | 0.80 | ALDH1A1 (0.45) | CYP3A4TP53HPGDSMN1; SMN2NPC1 | |
| SCHEMBL4458452 | 0.77 | ADORA3 (0.46) | CA1CA2CYP3A4ADORA3HPGD | |
| SCHEMBL15673590 | 0.77 | CYP2A6 (0.42) | CYP3A4MEN1KMT2APDGFRB | |
| SCHEMBL9414866 | 0.76 | ESR1 (0.57) | CYP3A4HPGDCYP19A1MEN1KMT2A | |
| SCHEMBL9624356 | 0.75 | ABCB1 (0.51) | CA1CA2CYP3A4TP53ABCB1 | |
| SCHEMBL5567669 | 0.74 | KDM4E (0.36) | TP53HPGDSMN1; SMN2NPC1CYP19A1 | |
| SCHEMBL5324075 | 0.72 | NPC1 (0.50) | TP53HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7972358 | 0.72 | CYP2A6 (0.38) | CA12TP53CA9HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117767-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2024-06-06 | — | — | WO | claimed |
| CN-114402451-A | Photoelectric conversion element and imaging element | 索尼集团公司 | 2022-04-26 | — | — | CN | claimed |
| CN-110739406-B | Organic electroluminescent device | 乐金显示有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-110739406-A | Organic electroluminescent device | 乐金显示有限公司 | 2020-01-31 | — | — | CN | claimed |
| EP-1628970-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes of Pharmaceutical Discovery, LLC (US) | 2006-03-01 | — | — | EP | claimed |
| US-6849629-B2 | Heteroaromatic substituted sulfonyl or sulfoxide or thio-pyridazinone derivatives, useful for treating diabetic complications and cardiovascular disorders | PFIZER, INC. (US) | 2005-02-01 | — | — | US | claimed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2004099192-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | claimed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | claimed |
| EP-0659193-B1 | PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 1997-12-10 | — | — | EP | claimed |
| CN-113727980-B | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-06-28 | — | — | CN | disclosed |
| US-12020872-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | Ambient Photonics, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024117767-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2024-06-06 | — | — | WO | disclosed |
| EP-3621957-B1 | FUSED STILBENE DERIVATIVES AS SOLAR CELL DYES | AMBIENT PHOTONICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
| EP-0659193-B1 | PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0659193-A1 | PLATELET AGGREGATION INHIBITORS | G.D. Searle & Co. (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5354738-A | Amino acid derivatives | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994005694-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12020872-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | FDFT1, SUN2, CDC73 | CA1 4332/4885CA2 3904/4885CYP3A4 1502/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | CA1 3476/4885CA2 782/4885CYP3A4 1647/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | CA1 3972/4885CA2 1112/4885CYP3A4 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.